DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1669.52T
5Y Perf.-59.8%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
DBVT vs SLRX
Revenue, margins, valuation, and 5-year total return — side by side.
SLRX
Salarius Pharmaceuticals, Inc.
Biotechnology
Market Cap$698K
5Y Perf.-100.0%
DBVT vs SLRX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | DBVT | SLRX |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $1669.52T | $698K |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-168M | $-5M |
| Total Debt | $22M | $222K |
| Cash & Equiv. | $194M | $2M |
DBVT vs SLRX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
DBVT
SLRX
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| DBV Technologies S.… (DBVT) | 100 | 40.2 | -59.8% |
| Salarius Pharmaceut… (SLRX) | 100 | 0.0 | -100.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: DBVT vs SLRX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: SLRX leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. DBV Technologies S.A. is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
DBVT
DBV Technologies S.A.
The Growth Play
DBVT is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth -100.0%, EPS growth -347.5%
- -87.1% 10Y total return vs SLRX's -100.0%
- Lower volatility, beta 1.26, Low D/E 12.8%, current ratio 3.67x
Best for: growth exposure and long-term compounding
SLRX
Salarius Pharmaceuticals, Inc.
The Income Pick
SLRX carries the broadest edge in this set and is the clearest fit for income & stability and defensive.
- Dividend streak 1 yrs, beta 1.10
- Beta 1.10, current ratio 1.98x
- -0.2% revenue growth vs DBVT's -100.0%
Best for: income & stability and defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | SLRX | -0.2% revenue growth vs DBVT's -100.0% |
| Quality / Margins | SLRX | 5.2% margin vs DBVT's 0.3% |
| Stability / Safety | SLRX | Beta 1.10 vs DBVT's 1.26 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | DBVT | +110.7% vs SLRX's -93.1% |
| Efficiency (ROA) | SLRX | -82.1% ROA vs DBVT's -89.0% |
DBVT vs SLRX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2020
DBVT vs SLRX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLDBVTLAGGINGSLRX
SLRXSalarius Pharmaceutic…
1leads
DBVTDBV Technologies S.A.
3leads
6 Total Categories
CATEGORYLEADERvs SLRXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
DBVT1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
DBVT4/7
Total Returns1Y, 3Y, 5Y total returns with dividends
DBVT5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
SLRX1/1
Income & Cash Flow (Last 12 Months)
DBVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
DBVT and SLRX operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | DBVTDBV Technologies … | SLRXSalarius Pharmace… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$112M | -$5M |
| Net IncomeAfter-tax profit | -$168M | -$5M |
| Free Cash FlowCash after capex | -$151M | -$4M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +91.5% | +84.1% |
DBVT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — DBVT and SLRX each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | DBVTDBV Technologies … | SLRXSalarius Pharmace… |
|---|---|---|
| Market CapShares × price | $1669.52T | $697,790 |
| Enterprise ValueMkt cap + debt − cash | $1669.52T | -$2M |
| Trailing P/EPrice ÷ TTM EPS | -0.74x | -0.01x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 0.64x | 0.03x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — DBVT and SLRX each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
DBVT leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
SLRX delivers a -117.8% return on equity — every $100 of shareholder capital generates $-118 in annual profit, vs $-130 for DBVT. DBVT carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to SLRX's 0.15x. On the Piotroski fundamental quality scale (0–9), DBVT scores 4/9 vs SLRX's 3/9, reflecting mixed financial health.
| Metric | DBVTDBV Technologies … | SLRXSalarius Pharmace… |
|---|---|---|
| ROE (TTM)Return on equity | -130.2% | -117.8% |
| ROA (TTM)Return on assets | -89.0% | -82.1% |
| ROICReturn on invested capital | — | — |
| ROCEReturn on capital employed | -145.7% | -168.7% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 3 |
| Debt / EquityFinancial leverage | 0.13x | 0.15x |
| Net DebtTotal debt minus cash | -$172M | -$2M |
| Cash & Equiv.Liquid assets | $194M | $2M |
| Total DebtShort + long-term debt | $22M | $221,866 |
| Interest CoverageEBIT ÷ Interest expense | -189.82x | — |
DBVT leads this category, winning 4 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
DBVT leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DBVT five years ago would be worth $3,041 today (with dividends reinvested), compared to $2 for SLRX. Over the past 12 months, DBVT leads with a +110.7% total return vs SLRX's -93.1%. The 3-year compound annual growth rate (CAGR) favors DBVT at 5.7% vs SLRX's -85.0% — a key indicator of consistent wealth creation.
| Metric | DBVTDBV Technologies … | SLRXSalarius Pharmace… |
|---|---|---|
| YTD ReturnYear-to-date | +2.3% | +13.3% |
| 1-Year ReturnPast 12 months | +110.7% | -93.1% |
| 3-Year ReturnCumulative with dividends | +18.1% | -99.7% |
| 5-Year ReturnCumulative with dividends | -69.6% | -100.0% |
| 10-Year ReturnCumulative with dividends | -87.1% | -100.0% |
| CAGR (3Y)Annualised 3-year return | +5.7% | -85.0% |
DBVT leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — DBVT and SLRX each lead in 1 of 2 comparable metrics.
Risk & Volatility
SLRX is the less volatile stock with a 1.10 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DBVT currently trades 74.4% from its 52-week high vs SLRX's 2.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | DBVTDBV Technologies … | SLRXSalarius Pharmace… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.26x | 1.10x |
| 52-Week HighHighest price in past year | $26.18 | $34.65 |
| 52-Week LowLowest price in past year | $7.53 | $0.52 |
| % of 52W HighCurrent price vs 52-week peak | +74.4% | +2.1% |
| RSI (14)Momentum oscillator 0–100 | 43.7 | 47.6 |
| Avg Volume (50D)Average daily shares traded | 249K | 79K |
Evenly matched — DBVT and SLRX each lead in 1 of 2 comparable metrics.
Analyst Outlook
SLRX leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
| Metric | DBVTDBV Technologies … | SLRXSalarius Pharmace… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — |
| Price TargetConsensus 12-month target | $46.33 | — |
| # AnalystsCovering analysts | 15 | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 0 | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
SLRX leads this category, winning 1 of 1 comparable metric.
Key Takeaway
DBVT leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). SLRX leads in 1 (Analyst Outlook). 2 tied.
Best OverallDBV Technologies S.A. (DBVT)Leads 3 of 6 categories
Loading custom metrics...
DBVT vs SLRX: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is DBVT or SLRX a better buy right now?
Analysts rate DBV Technologies S.
A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — DBVT or SLRX?
Over the past 5 years, DBV Technologies S.
A. (DBVT) delivered a total return of -69. 6%, compared to -100. 0% for Salarius Pharmaceuticals, Inc. (SLRX). Over 10 years, the gap is even starker: DBVT returned -87. 1% versus SLRX's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — DBVT or SLRX?
By beta (market sensitivity over 5 years), Salarius Pharmaceuticals, Inc.
(SLRX) is the lower-risk stock at 1. 10β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 15% more volatile than SLRX relative to the S&P 500. On balance sheet safety, DBV Technologies S. A. (DBVT) carries a lower debt/equity ratio of 13% versus 15% for Salarius Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — DBVT or SLRX?
On earnings-per-share growth, the picture is similar: DBV Technologies S.
A. grew EPS -347. 5% year-over-year, compared to -1522. 7% for Salarius Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — DBVT or SLRX?
DBV Technologies S.
A. (DBVT) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Salarius Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DBVT leads at 0. 0% versus 0. 0% for SLRX. At the gross margin level — before operating expenses — DBVT leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — DBVT or SLRX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is DBVT or SLRX better for a retirement portfolio?
For long-horizon retirement investors, Salarius Pharmaceuticals, Inc.
(SLRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 10)). Both have compounded well over 10 years (SLRX: -100. 0%, DBVT: -87. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between DBVT and SLRX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.